Home

Christopher Hite

CIK 1814238 · EVP & Chairman, Partnering · last filed 2026-08-19

Christopher Hite is an EVP & Chairman, Partnering who has filed 21 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for RPRX, was dated Aug 19, 2026. Across all open-market trades the lifetime net is −$19.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$23.07M

Companies

4

Total Filings

21

Lifetime Open-Market Net

-$19.54M

Filer Profile

Reported Address
C/O ACCELERON PHARMA INC.
128 SIDNEY STREET
CAMBRIDGE, MA 02139
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RPRX EVP & Chairman, Partnering 393,601 $58.61 $23.07M -$19.54M 15 2026-08-19
KLRA Director — $13.94 — $0 1 2026-04-20
VERA Director — $35.05 — $0 1 2026-03-09
ACCELERON PHARMA INC (XLRN) Delisted Director 0 $178.75 $0 $0 3 2021-11-22

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 RPRX Mixed −116,800 -$6.00M EDGAR
2026-08-07 RPRX Grant (A) +11,002 $0 EDGAR
2026-08-07 RPRX Grant (A) +11,002 $0 EDGAR
2026-07-02 RPRX Sell (S) −130,000 -$7.35M EDGAR
2026-06-25 RPRX Sell (S) −150,000 -$8.16M EDGAR
2026-06-23 RPRX Notice (144) −30,000 -$1.66M EDGAR
2026-05-08 RPRX Grant (A) +24,263 $0 EDGAR
2026-04-20 KLRA Grant (A) — $0 EDGAR
2026-03-09 VERA Grant (A) — $0 EDGAR
2026-02-13 RPRX Grant (A) +26,626 $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.